KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Revenue: 2009-2024

Historic Revenue for Neogenomics (NEO) over the last 16 years, with Dec 2024 value amounting to $660.6 million.

  • Neogenomics' Revenue rose 11.90% to $187.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $709.2 million, marking a year-over-year increase of 10.10%. This contributed to the annual value of $660.6 million for FY2024, which is 11.65% up from last year.
  • According to the latest figures from FY2024, Neogenomics' Revenue is $660.6 million, which was up 11.65% from $591.6 million recorded in FY2023.
  • In the past 5 years, Neogenomics' Revenue ranged from a high of $660.6 million in FY2024 and a low of $444.4 million during FY2020.
  • Over the past 3 years, Neogenomics' median Revenue value was $591.6 million (recorded in 2023), while the average stood at $587.3 million.
  • Data for Neogenomics' Revenue shows a peak YoY climbed of 16.07% (in 2023) over the last 5 years.
  • Neogenomics' Revenue (Yearly) stood at $444.4 million in 2020, then increased by 8.97% to $484.3 million in 2021, then grew by 5.24% to $509.7 million in 2022, then climbed by 16.07% to $591.6 million in 2023, then grew by 11.65% to $660.6 million in 2024.